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THE CLINICAL UTILITY OF CONCOMITANT PTEN AND FAS DELETION AS AN
EARLY INDICATOR FOR PROSTATE ADENOCARCINOMA SUBTYPES THAT LEAD TO
EXTRACAPSULAR METASTASIS

An Abstract of the Thesis by
Brendan James-Truman Coulter

The utility of genes PTEN and FAS as prognostic markers for the identification of early
and/or aggressive prostatic adenocarcinomas is seemingly validated in the study results we
obtained using fluorescence in-situ hybridization (FISH) of archived paraffin embedded surgical
prostate core biopsy samples obtained from two CLIA and CAP licensed anatomical pathology
labs (Bostwick Laboratories, Uniondale, NV and GoPath Laboratories, Buffalo Grove, IL). From
early benign subsets of sample cases to aggressive extracapsular invasive tumors, the presence of
random deletions evolves into clonal populations of co-deletion of both genes at question. We
identify independent research that demonstrates the ability of these two genes to work together in
a pathway of rapid cell division and then (or sometimes concomitant) evasion of said neoplastic
tumor cell lines from innate cell mediated immunity. Sample size limitations limits predictive
values in our study, however this research adds credence to personal anecdotal observation I have
made in the past in the capacity of FISH clinical operations and validation management and
personal “bench work.” Further, since the onset of our research, using a completely different
modality, scientists have studied the same markers together and reached the similar if not the
same conclusions.
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CHAPTER I

INTRODUCTION

According to the American Cancer Society there will be 233,000 new cases of prostate
cancer diagnosed in 2014. Of these, 29,480 will be terminal. ACS reports that for the same year,
prostate cancer (PC) will be the second most common cause of death from cancer in the United
States.
The World health organization’s HDI (Human Development Index) categorizes more and
less developed regions of the world based on economy, literacy rate, access to health care as well
as other factors. In addition, they gather data as it relates to the incidences, mortality and the
projected growth of the various forms of cancer throughout the world. In a recent published report
by the WHO affiliated International Agency for Research on Cancer (Cancer Research UK, Jan.
2014), HDI and regional cancer statistics were combined. The results show the unmistakable
trend of prostate cancer (incidences and deaths) increasing relative to increases in the HDI. Even
more disturbing, this same article ranks PC (+3%) at the top of the projected growth percent for
2030 as well as five other common cancer types (Lung (+1%), Colorectal (+1%), Breast (+2%),
Cervical (+2%) and Stomach (-2.5%). In the past several decades, clinical screening tests,
especially Pap smears, have proven to be effective in preventing low grade squamous
intraepithelial lesions (LGSIL) from developing into higher grades including cervical squamous
or adenocarcinoma.
In a report published by the Journal of Clinical Oncology¹ found that expensive new
treatments for prostate cancer such as IMRT (intensity modulated radiation therapy), laparoscopic
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or robotic MIRT’s (minimally invasive radiation therapy) and brachytherapy (seeding) with or
without radiation therapy increased dramatically between 2002 and 2005. Clearly there is a need
to try and push the strategy to beat prostate cancer away from exorbitantly priced treatments, to
more affordable, more beneficial forms of preventive medicine (molecular diagnostics or
prognostics and the development of pharmaceuticals with the insight molecular pathology and
cytogenetics offer).
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CHAPTER II

DIAGNOSTICS

Current prostate screening methods are either unreliable or invasive. In cervical cancer
cytology based Pap Smears combined with Human Papilloma Virus (HPV) molecular based virus
identification are both non-invasive, inexpensive and highly reliable (i.e., when Pap test is
combined with HPV molecular testing). Prostate screening has historically relied on two
screening modalities. One type uses quantitative analysis of a specific protein obtained from
blood samples. This protein, the prostate specific antigen (PSA) is detected and quantified using
traditional clinical chemistry methods. According to the Mayo Clinic website, limitations of the
PSA assay are PSA-raising factors such as benign hyperplasia, inflamed and infected prostate
lowering factors like BPH or urinary drugs or chemotherapy agents, inaccurate results, and
over-diagnosis in that many of the tumors will not progress to detectable symptoms in their
lifetime. The second method of screening is based on the surgical removal of a needle core
biopsy from specific regions of the prostate gland. Following this surgery the specimen is
processed for histopathological analysis. By its very nature, prostate surveillance is hampered by
masculine psychological and societal attitudes with regards to the disease. Historical cultural and
behavioral problems seem to be an intrinsic limitation of prostate screening partly due to the
invasive nature of the standard diagnostic assays.
The evolution in diagnostics of prostate cancer beyond simple stains and counter-stains
like H&E (Hematoxylin and Eosin respectively) follow a path that is the antithesis of Francis
Crick’s central dogma² IE DNA-RNA-Protein. Thus the recent history of cancer diagnostics
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follows the detection of specific proteins associated with cancer, to the detection of RNA
molecules that code for the protein products related to cancer. Now we are finally beginning the
herculean task of identifying genes and chromosomal aberrations that relate to cancer. This effort
begins with a search for larger microscopic features such as chromosome size/number and
progresses to an examination of nuclear: cytoplasmic ratios and eventually the spatial relationship
between nuclei, cells and adjoining tissues. Early stains relied on variations in staining dependent
upon variations in cell structure and pH. These early differential or counter stains were the first
step toward focusing on those cellular characteristics deemed most clinically significant.
The first step away from early types of stains occurred in 1941 by Gomori. In his paper³
uses the differential stain chromium hematoxyln-phloxin. He describes a specific staining
capability that utilizes the basic environment produced by the insulin producing β cells (Islets of
Langerhans) to differentially stain, both directly and indirectly, for the presence insulin. This
ushered in the era of special stains.
In reality, any stain that is not an H&E stain is a special stain. The main body of special
stains lies in immunohistochemical (IHC) staining or immunofluorescent staining. These stains
can be visualized by traditional bright field microscopy or fluorescence microscopy. The origin of
this method can be traced back to 19424. According to a paper written to dedicate the
contributions of Albert H. Coons the author (Karnovsky)5describes the formulation of a rather
straightforward approach at selecting antibodies that are specific for the antigenic epitope of
choice (proteins involved in normal or carcinogenic processes), and then labeling by color or
fluorescent tags for microscopic analysis.
IHC for prostate includes several stains. Key among them is P63, which is a homolog of
the P53 tumor suppressor gene (P53 and P63 can used both diagnostically and prognostically).
P63 is expressed in the basal cell layer of the epithelium and is involved in embryogenesis.
CK903 and Cytokeratin 34 beta E12 are basil cell specific anti-keratin antibody stains that when
positive rule out PC, but when negative do not automatically indicate PC. AMACR and P504S
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are positive in PC lesions and positive in benign lesions. In other words, this is a positive dual
stain that allows for the differential diagnosis of PC vs. benign tumors. Other positive stains
include low molecular weight cytokeratin, EMA and CEA. Negative stains include CD10, Muc6
(normal in lipochrome laden seminal vesicle cells), CK7, CK20 and thrombomodulin. High grade
PC (Gleason 8-10) do not express the proteins these negative stains pick up. In an attempt to
supplement positive AMACR IHC researches have directed their attention to the Fatty Acid
Synthetase6. Using microarray or advanced sequencing analysis, studies have shown increases in
production of FASn RNA molecules as a backdrop, Wu and associates were able to demonstrate
increased expression of FASn PC glands by IHC. Although FASn expression is used as a positive
diagnostic marker when up-regulated, we will see that there is a dichotomy to this extraordinary
gene, and in fact, it may play a key role in the ability of a tumor suppressor (PTEN) to evade the
patients cell mediated anti-cancer immunological response. We now find ourselves at the
transition point from diagnostic protein and RNA analysis, to gene and chromosomal
prognostication.
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CHAPTER III

PROGNOSTICS
“It appears to me a most excellent thing for the physician to cultivate Prognosis; for by
foreseeing and foretelling, in the presence of the sick, the present, the past, and the future, and
explaining the omissions which patients have been guilty of, he will be the more readily believed
to be acquainted with the circumstances of the sick; so that men will have confidence to entrust
themselves to such a physician” (Hippocrates, The Book of Prognostics 400 B.C.E.)7. The art
The Science of prognostication and its implementation as a viable medical objective or tool is not
new. In CAP Foundation’s (Conference Series Futurescape of Pathology 2008)8 Jennifer Hunt
MD of the Cleveland Clinic describes the time-line of diagnostics and prognostics as it relates to
the technology of the day. Where 1500-1800 represented the period of gross examination as a
way of achieving these goals. The period between1800-1930 was dominated by microscopic
analysis. Next electron microscopy gave us deeper insight from 1930-1980. IHC followed from
1980-2000 and has been the standard tool to differentiate (diagnostics) types of tumors, and give
us deeper insight into the biology of the individual’s cancer (biomarker prognostics). At the turn
of the millennia, DNA and the emerging disciplines (e.g., FISH, PCR and next-generation
sequencing) are now growing into their place as the yardstick for detecting cancer, predicting
outcomes, and hopefully providing opportunities for developing therapeutic strategies to defeat
the cancer that is specific even for a single individual.
Arguably the modern age of prognostics started in 1932 with the classification scheme set
forth by Cuthbert E. Dukes9, whereby he uses a staging system to determine the overall lethality
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of the rectal cancer. If the cancer is confined to the rectal tissue there is a better prognosis. If
growth is seen in the extra-rectal tissue, the prognosis is poorer, and even worse predictions of the
poorest outcomes are seen in patients where the cancer has metastasized to regional and distant
lymph nodes respectively. For the most part, traditional pathology, and even diagnostics, relies on
the identification of a normal vs. atypical state or condition. In short, it is the phenotypic or
genotypic comparison between abnormal and normal. This can be on an organismal, tissue,
cellular and even molecular level. Prognostics and modern therapeutics however, rely on a much
deeper understanding of interactions between all of the aforementioned levels. Today’s
prognostics mostly involve the identification of genetic alterations and the subsequent proteins,
pathways and extracellular signaling that are directly affected by these alterations. At center stage
are the genes and proteins classified as oncogenes and tumor suppressor genes.
The first oncogene or proto-oncogene was discovered in 1970. However, events dating
back to 1909 lead to this discovery. In a paper describing the “road to discovering” the first protooncogene10 details the first breakthrough as the point when they identified a hen’s tumor cells
being transplantable to chickens of the same species11. They determined that the transformative
agent was a non-cellular filterable particle. Later studies showed that the virus often had
replicative capacity but not transformative (cancer causing) capability and vise-versa. This in turn
lead to studies that helped implicates the host genome in the transformation process. Finally, with
the help of more modern molecular biology techniques, the first proto-oncogene c-SRC was
discovered. Hence, the presence of this gene can be used in the prognostication of sarcoma.
Oncogenes convey carcinogenic properties by producing proteins that ramp-up cell cycle
division, whereas tumor suppressor genes code for proteins that in essence keep the cell cycling
in check. When deleted, tumor suppressor genes can cause cancer or make it significantly more
aggressive. Arguably two of the most significant tumor suppressor genes discovered were p53
and PTEN. PTEN (phosphatase and tensin homolog) or MMAC1 (mutated in multiple advanced
cancers) are the same protein and were discovered simultaneously by researchers Li and Steck
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respectively in 199712. Subsequent studies have helped cobble together a picture of this amazing
gene’s role in tumor suppression, and embryogenesis and even apoptosis. In a review article
published in 2004 by the Medical Science Monitor, Eric C. Chu and Andrzej S. Tarnawski13
outline the known basic involvement of the PTEN protein in tumor suppression. It starts with the
molecular structure and its dual enzymatic capacity. In that they have both protein phosphatase
and lipid phosphatase activity. Like so many other critical proteins, PTEN is involved in a multitiered pathway that affects cell cycling, growth and apoptosis. They describe the protein as having
two domains and a tail section. The first motif is made up of the N-terminal region which consists
of the Phosphatase domain. This is purportedly responsible for the tumor second motif is made up
of the C-terminal region which consists of the C2 domain and the tail or PDZ domain. The C2
domain is responsible for PTEN’s affinity for phospholipids. This allows for PTEN to be placed
appropriately for a signal transduction cascade that involves many proteins. The tail domain
contains protein kinase CK2 phosphorylation sites which allow for stability and activity of the
protein. The general pathway starts with PTEN positioning itself on the membrane proximal to a
tyrosine kinase receptor which as yet is not fully understood, The other major well documented
area of clinicopathological and molecular diagnostics and prognosis are the and ETS (MAINILY
TEMPRSS-ERG) fusion related family destruction.
Prostate cancer displays a “multifocal” pattern when observed in traditional morphologic
histopathogical analysis, whereby this cancer (PcA) has demonstrated upwards of 79% multifocal
distribution in one large study by Yoshimoto14 which included 142 prostatectomy specimens all
positive for PCA. Further, this multifocal characteristic is accompanied by varying genetic
heterogeneity. As mentioned above, the two major genetic alterations are the ETS genomic
rearrangements and PTEN loss. According to this study, albeit commonly seen together, PTEN
loss has a stronger correlation with higher Gleason score than ETS by itself 15. It has therefore
been determined that PTEN loss demonstrates the ability to be a more useful early biomarker for
the detection of aggressive cancers. In fact, 35-58% of advanced cancers have PTEN loss either
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as hemizygous or homozygous. As they point out, however, the ETS rearrangements likely play
an important role in prostate cancer progression due to the involvement of its promotor region
driving the expression of the fused ETS gene.
This is the main crux of this study. Since there is a lack of correlation between ETS
rearrangements and high Gleason score, could there not be some other “genetic factor” that drives
the clonal populations towards aggressiveness independent or in combination with a completely
different mode of clonal expansion and metastatic potential. As we will see, there might be
something going on with the PTEN loss or more accurately its loss and the concomitant loss of its
proximal gene FAS and its relationship to apoptosis and cell mediated immunological cancer
destruction.
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CHAPTER IV.

PTEN RESERCH

When trying to determine the clinical outcome of prostate cancers with Gleason scores
remain the best prognostic markers. With a grant from the Canary Foundation, a multicenter
retrospective study was performed using tissue microarrays (TMA) to study PTEN. The majority
of positive core biopsies performed on patients result in a score of 6 or 7. However, upon radical
prostatectomies performed on the same patients 14-51% and 9% were downgraded (Troyer,
2015). Another study has shown that clinical stage, which is the second most used indicator does
not help predict the final stage16. According to the Canary study, of the 55 tumors with
homozygous deletion 16 had interstitial deletions involving PTEN alone retaining both flanking
genes in the 4 probe cocktail (fig 5) and 39 homozygous deletions having deletions of all three
genes (WAPAL, PTEN & FAS). Interestingly, without explanation, they consider the deletion of
all three genes as mere artifacts. They might be artifacts in as far as their research is concerned
but their ubiquitous presence in certain clonal populations make it worthy of investigation in
order to rule out their potential to the overall transformation from indolent to more aggressive
forms. Further they report undeleted cases as correlating to Gleason 6 while having a Gleason
score of 8 was more associated with homozygous deletions. As will be seen, these results are
contrary to what was observed in my research.
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CHAPTER V.

FAS RESERCH

Fatty acid synthase or FAS (also known as APO-1 and CD95) is a gene that codes for the
FAS ligand and the FAS cell surface receptor which are part of the super family TNF. The
interaction of this receptor by the FAS ligand has been well documented to induce apoptosis. It
was first identified by a study done in 1989 by BC Trauth17 in the American Journal of Medicine.
They were able to induce apoptosis with the use of a monoclonal antibody directed at the FAS
cell surface receptor. FAS is one of the destruction pathways used by cytotoxic T via MHC class I
cells to induce apoptosis18. These researchers also note that experimental introduction of DNA
damage causes a marked upregulation and overexpression of both the FAS ligand and cell surface
receptor. It is therefore possible for cells undergoing significant genomic stress to upregulate
these proteins, which in turn find their way to the cell membrane and engage to form a complex
that ultimately interacts with several intermediate proteins and complexes. These intermediates
are eventually able activate the protease caspase 8 and finally caspase 3 (fig 7) which cleave
substrates like the nuclear lamins, actin filaments as well as enzymes responsible for DNA repair.
DNA fragmentation is often associated with end stage apoptosis. Up regulation and presentation
of the FAS ligand is known to be associated with cytotoxic T cells thereby making them
“weaponized.” This affords lymphocytes the ability to interact with and turn on the self-destruct
triggers in said stressed or compromised cells (e.g., cancer). Interestingly this article points to the
use of anti-FAS antibody in the treatment of certain diseases such as glumerulonephritis, arthritis
and other systemic autoimmune diseases.
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Over expression of FAS in PCA has been demonstrated in several studies. On the surface,
no pun intended, the over expression of FAS would seem to rule it out as an early biomarker for
aggressive type prostate tumors. However, like the presence of FAS mutations in the precursor
lesions known as PIN (prostatic intraepithelial neoplasia, Bostwick19), and the subsequent lack of
mutation in the FAS gene in higher grade neoplasia,20 later over expression does not rule out its
role in the early pathogenesis of aggressive PCA. It is this conundrum, in my opinion, that elicits
the premature conclusion by the above mentioned Troyer and colleagues use to describe the loss
of FAS as a mere artifact.
Figure 1A.
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CHAPTER VI.

MATERIALS AND METHODS

Quality Control
Probe were stored at -20°, protected from light. Excess freeze/thaws cycles were avoided.
Probe were not used beyond their expiration date shown on vial. All reagents were molecular
grade. Reagents were labeled, dated, and all prepared reagents were initialed. Parallel test were
performed on all newly prepared reagents with reagents that have passed manufacturing QC
requirements. Reagents were prepared and pre-warmed in advance when applicable. Equipment
was routinely calibrated according to CLIA standards. Control slides were run concurrently with
patient slides to monitor their assay performance and to assess their accuracy of signal
enumeration. Control slides were used beginning with the de-paraffinization process onward.
Reagents were required to reach their desired temperatures prior to initiating the procedure. DNA
probe were validated with established cut off values. Each hybridized slide was evaluated against
quality parameters determined by the laboratory. FISH assay results were considered not to be
informative if the specimen quality and/or specimen slide preparation was inadequate. A rigorous
quality check was performed before scoring.
Preparations required before starting procedure
2ul specimen sections were baked for 3 hours to overnight at 56° C. All reagents and
stock solutions were prepared prior to the start of teach procedure. Care was taken to make sure
slides were labeled correctly: probe ID, date, and study number. If an H & E slide corresponding
to the FISH slide was available a pathologist demarcated the area of interest, corresponding slide
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areas were marked on the test slide with a diamond tipped pencil on the backside of specimen
slides(s) prior to processing. Focus on these areas was given when analysis was being performed.
Equipment
Fluorescent microscope equipped with recommended filters: DAPI, Aqua, Orange,
Green, and Red Phase contrast light microscope, Fume hood, Micro-pipettor (1-20 µl), 20-200
µl), 100-1000 µl), Timer, Magnetic stirrer, Vortex mixer, Microcentrifuge, Water baths,
Thermobrite or hybrite, pH meter, Hot air oven (56°C), Leica Ariol scanning System
Materials
Calibrated thermometers, Micro test tube racks, Rubber cement, 2 microns section of
positively charged or,silicanized microscope slides, Glass coverslipps-22x22mm or 24x50 mm,
Polypropylene micro centrifuged tubes, (1.5ml), Graduated cylinders, Forceps, Coplin jars note:
gradually heat glass Coplin jars up to 72-80°C otherwise they will crack, Anhydrous Ethyl
Alcohol. Store at room temperature. Open in fume hood 20x SSC, NP40 or Igepal. Store in dark
2-8°C, DAPI II store at -20°C, Micropipettor tips 10, 200, 1000, Stir bars, HCl 1.0N soln, 12 N
HCl, NaOH 1.0N soln, Pepsin Powder, Laboratory wipes, Pyrex bottles -250-500ml, 1L, 1L
volumetric flasks, DAPI II counterstain (Vysis), Triton X, EDTA, NaBH4, DiH2O, 10% Neutral
Buffered Formalin (NBF)
Reagents Preparation
1X PBS (pH7.2-7.4)
100mL 10X PBS + 900ml Deionized water
1% Formaldehyde:
125 ml of 10% NBF
370 ml of 1X PBS
5 ml of 100X MgCl2.
Store at 2-8°C.
Denature solution: (pH 7.0-8.0) (70% Formamide/2X SSC):
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350 ml Formamide, 50 ml 20X SSC, and 100 ml DI water.
Store at 2-8°C.
1mM EDTA
20X SSC (using 20X SSC powder)
264g 20XSSC + 900ml of DiH2O. Mix thoroughly.
Adjust pH to 7.0 and adjust volume to 1L with additional water. Store at 2-8° for 6 months.
20X SSC
Dissolve the following in 800ml of DiH20:
175.3g NaCl and 88.2g NaCitrate
Adjust the pH to 7.0 with a few drops of 1N HCl or 1N NaOH and adjust the volume to 1L with
additional DiH20. Store at 2-8° for 6 months
2X SSC
100ml 20XSSC
900ml DiH2O
pH to 7.0-7.5. Store at 4-8°C.
Wash Solution (0.2XSSC/0.3%NP-40) (1 Liter)
10mL 20X SSC
3mL NP40
Bring up to 1 liter with DiH2O.
pH to 7.0-7.5. Store at RT.
0.01N HCl (pH 2-2.5)
833µL of 12N HCl into 1L DiH2O
Pepsin
Stock Pepsin: 10g pepsin to 100ml of purified water
Aliquot into ~7mL tubes, freeze, expires in 3 months.
Working pepsin: Add 6.6ml of thawed and mixed Stock Pepsin solution to 500ml of 0.01N HCl
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Triton
Stock Triton Solution:
25ml of 2M MgCl2
125ml of 10X PBs
850ml of DiH2O
Working Triton Solution:
500mL stock triton solution
2.5mL Triton X
NaBH4
Use 1mg of NaBH4 per one milliliter of 1XPBS
Probe
3-5µL of Cymogen DX (Irvine, CA) PTEN Del-Tect™ Four Color Probe
Procedure
Specimens were cut to 2µm sections from blocks; slides were baked in oven at 56°C for 3
hours or overnight. Manual Deparaffinization. Slides were immersed in xylene for 2 minutes x
5changes in a fume hood. Slides were immersed in 100% EtOH for 2 minutes x 5 changes in
fume hood. Slides were rinsed in diH2O x 3 changes. Antigen retrieval was performed in with 1
mM EDTA in pressure cooker for 25 min >125° C. They were then rinsed in deionized water 3-4
times. Slides were taken out and until they cooled down. Slides were placed in 1mg/ml
NaBH4/1XPBS solution for 10min, and then repeated in fresh solution for 10min, then rinsed in
several changes of water. Slides were run on Vysis processor using the standard tissue protocol.
FISH probes were thawed at RT for 10 minutes, vortexed briefly and microcentrifuged
for 5-10 seconds. The probe was then warmed so that the viscosity decreased sufficiently to allow
accurate pipetting. 3-5ul was added, with the appropriate amount of anti-fade reagent, to the
tissue area on the slide, and placed and appropriate sized coverslip was placed on probe area.
Bubbles were removed by gently massaging them out using our finger nail. Coverslips were
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sealed with rubber cement. Thermobrite was set to 83°C for 5 minutes (the co-denature step) and
then 37°C for 16-24 hours for hybridization. Moisture strips soaked with dH2O and place in the
slots in the Thermobrite. Test slides were placed flat in the center position to outside. The lid was
closed and the program ran. The Thermobrite was not reopened for 16 hours. Probes were
refrozen @ -20°C. 0.2 XSSC/0.3% NP40 was warmed (~45min) in a water bath. The
temperature was double checked for the hot wash solution by inserting a thermometer directly
into the solution, before and after sample slide were added. The solution had to be at 50° +/- 1°.
Rubber cement was removed from the slide. Slides were placed in RT 2XSSC for 5 min. and
agitated to remove the coverslips. If coverslip did not come off, the coverslips were gently moved
to the edge of the slide and flicked off with the fingernail or forceps. Slides were washed in the
hot wash mixture for exactly 2 minutes at 50°C, while gently agitating the first 30 seconds. Slides
were transfered to fresh 2XSSC at RT briefly. Air dry slide in dark drawer. Thaw DAPI II
counterstain. Vortex and pulse microcentrifuge DAPI II. Add 10-15µl DAPI II to the tissue areas
on the dry slide. Coverslip slide and refreeze DAPI II. Place slide in a slide tray in the freezer for
~ 30 min or until ready to analyze.
Controls
Control slides had to be run concurrently with patient slides in order to monitor the
assay’s performance and to assess the accuracy of signal review. One positive control slide had to
be processed for each specimen processing run, and with each new kit lot. Included was a
parallel patient slide (previously tested) every time newly prepared reagents were used.
Specimen Requirements
Specimen Type(s) including minimum volume/amount to perform assay: Specimen type
PTEN/FAS FISH prostate biopsy FFPE slides. Minimum volume/amount: 2µm sections from
tissue block. Specimen collection stability and handling: Specimens had to be fixed in formalin
24-48 hours of collection. PTEN/FAS FISH assay was performed within 4 weeks of the slide
preparation for optimal results. Unacceptable samples/specimen rejection criteria. An analyzed
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specimen was eliminated if the following conditions /criteria occurred: Section cut from tissue
block and placed on slide was non-representative of original histological diagnosis. Specimen in
which the representative tissue was exhausted during the histological diagnostic process. Poor
hybridization (e.g. week or no signals) resulted in equivocal interpretation. Samples that were not
received in formalin in the histology lab. Samples that were not embedded in paraffin.
Principles of Fish Evaluation
When evaluating the results of FISH, several factors were kept in mind: the architecture
of the tissue, including local variations in neoplastic cell content, fixation, and tumor cellularity
within the section; the frequent presence of truncated nuclei; and the complex nature of genetic
arrangements that were seen in some neoplasms.
Enumeration guidelines for deletion of locus-specific probe on formalin-fixed paraffinembedded (FFPE) tissue was provided. Typically, areas selected for FISH evaluation were
marked on a Hematoxylin and Eosin (H & E) stained slide that were directly adjacent to section
being used for FISH. Areas of the FFPE section selected for enumeration had to pass rigorous
quality criteria as being suitable for FISH analysis as detailed below.
Evaluation of Selected Areas (marked with diamond pen on back of slide)
Hybridized slides were evaluated for the specificity of the hybridization, the probe signal
intensity and the signal to background noise was determined so the hybridization was optimal for
the given analyses. Typically, at least 85% of all nuclei in the target area were easily enumerable.
There was a minimum background or nuclear fluorescent "noise". The FISH signal intensity was
consistently greater than background intensity in the regions of the slide chosen for analysis.
Thus, background noise was recognized by their lower intensity of the probe signal and different
shape.
The target area was scanned using a low power objective to examine cell distribution.
FISH analysis was normally focused on areas richest in abnormal cells. Variability most often
was observed within the section in terms of tissue preservation and morphological detail. It was
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useful to keep a conventionally H&E stained section for reference. Select of several areas was
chosen on the tissue where the cells were evenly distributed yet at a density that several nuclei
could be evaluated at 40x objective.
Areas were avoided where the borders of individual nuclei were not clearly identified
and/or high cell density caused excessive nuclear overlapping. At the same time the quality of the
tissue section was reviewed, the FISH signals were assessed by selecting and looking for the
areas with the brightest, most distinct signals while simultaneously having a low background
“noise.” This made individual nuclei more distinct and easier to enumerate. In general nuclei
were selected that had the same intensity and the DAPI staining was mostly uniform.
The shape and appearance of the DAPI was compared to the H&E or
immunohistochemical stained nuclei with a focus on the morphological characteristics of the cells
and the histological patterns of the tissue.

Figure 1B. Areas of interest marked on the H&E slide by the pathologist.

Selection of Nuclei to Score
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The selection of nuclei to score was a distinct step from the actual enumeration of probe
signals. In a given field of view, the nuclei were scored and first selected on the basis of the
criteria listed below.
Enumeration of the nuclei meeting these criteria were scored in an unbiased fashion.
DAPI/Morphological Criteria:
Nuclei had bright and uniform DAPI staining. Within adequate specimens, interphase
cells were required to be well defined and non-disrupted. (Figure 2A)
A. Prostate cancer cells were selected on the basis of their large size, well-round nucleus
that was located near the central focal plane (Figure 2B). Small nuclei or nuclei that
were below average size were not selected as they may have had truncation affect due
to the sectioning process. (Figure 2C)
B. The slide preparation required that they not be under-treated to the point of
preventing clear identification of the nuclear borders. Over-treated samples had a
doughnut-like appearance, with the nuclear contents missing from the center and
were not enumerated. (Figure 3)
C. Tumor nuclei could not be covered by a cloudy yellowish layer or obscured by autofluorescent structures.
D. Nuclei were examined that were well separated from each other (touching or
overlapping nuclei were avoided). (Figure 2D)
E. The nucleus had to have a consistent size at extreme focal planes along the z-axis.
This would ensure that the maximum volume of nucleus was present, minimizing
sectioning artefacts (Such nuclei would have been considered “intact” nuclei).
(Figure 4)

Figure 4:
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ENUMERATION OF SIGNALS
Having selected the optimal group of nuclei to score in the given field of view, I
proceeded to enumerate the probe signals in the unbiased manner described above. I scored only
those cells with red (centromeric) signals. This PTEN deletion probe set probe included four
probes, each labelled with a different fluorophore. Each probe was enumerated on its own using a
single narrow band pass filter. Beginning with the first probe color and its appropriate filter (FAS
and aqua or PTEN and RED), I enumerated the signal in a given cell, and proceeded or toggled to
the next color/filter. I repeated this until all the probes and colors were enumerated for a given
cell. The number of signals in the nucleus selected for enumeration were recorded separately on
the score sheet. Only cells with 2 red (centromeric) signals were enumerated. It was usually
necessary to focus up and down in the z-axis of the focal plane to accommodate the different
spatial configurations the probe signals occupied within the nucleus. In some cases, paired signals
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would appear. I counted paired signals (two smaller signals in very close proximity, with distance
between them less than the size of one signal) as one signal. Following DNA replication during
mitosis, some nuclei may present paired signals, two smaller signals in very close proximity.
These paired signals represent a single chromosome already replicated into sister chromatids. I
evaluated split or questionable signals by observing at higher magnification. I counted only
nuclei, in which a definite enumeration could be made, I did not analyze or enumerate
inconclusive cells. I did not evaluate interphase nuclei with multiple signals located on the
extreme periphery of the nucleus. I recorded accurately the signal count from each cell. When the
boundary of visible or interpretable nuclei is reached I skipped to the next field of view and
continued the scanning process. Moving from left to right (or top to bottom) I continued to scan
the slide for fields with evaluable nuclei. I repeated this scanning process until the appropriate
number of nuclei was enumerated (50 or more were enumerated depending upon the prevalence
of the abnormal cells and the area of interest is analyzed).
Figure 5:

The PTEN probe consists of four colors: red, orange, green, and aqua. The red fluor localizes to
the centromere of chromosome 10, while the orange fluor is specific for the gene of interest
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(PTEN). The green fluor localizes to the WAPAL gene and is centromeric to PTEN, while the
aqua fluor localizes to the FAS gene and is telomeric to PTEN
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CHAPTER VII.

DATA ANALYSIS

FISH results for this study were performed using the same clinical accuracy results
obtained in laboratory in which the results for this research project was completed using the ASR
(analyte specific reagent) validation parameters required by CLIA (Clinical Laboratory
Improvement Amendments). This included parallel results from Bostwick laboratories in New
York and Orlando, reproducibility (precision) using 3 positive and 3 negative, two technicians
over the course of 3 days each having a different “running” of samples, sensitivity and specificity
using known (known conventional surgical pathology diagnoses) and positive threshold (see
Figure 6 FAS/PTEN CUT-OFF below) cutoffs using cases obtained exclusively for this research
project.
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PRECISION
TABLE 1. DAY 1, RUN 1, TECHNOLOGIST 1

CASE #

Hemizygous
deletion
(% of cells)

Homozygous
deletion
(% of cells)

FISH INTERPRETATION

Abnormal/ Hemizygous

1

Val0020908

26

8

2

Val0022175

4

34

3

Val0026865

22

2

Abnormal/ Hemizygous

4

Val0018480

8

4

Normal/ Diploid

5

Val0018585

0

0

Normal/ Diploid

6

Val0018540

8

6

Normal/ Diploid

Hemizygous
deletion (% of
cells)

Homozygous
deletion (% of
cells)

FISH INTERPRETATION

Abnormal/ Homozygous

TABLE 2. Day 1, Run 1, Technologist 2

CASE #

1

Val0020908

30

6

Abnormal/ Hemizygous

2

Val0022175

14

36

Abnormal/ Homozygous

3

Val0026865

22

6

Abnormal/ Hemizygous

4

Val0018480

12

4

Normal/ Diploid

5

Val0018585

2

0

Normal/ Diploid

26
6

Val0018540

8

10

Normal/ Diploid

TABLE 3. Day 2, Run 2, Technologist 1

CASE #

Hemizygous
deletion
(% of cells)

Homozygous
deletion
(% of cells)

FISH INTERPRETATION

1

Val0020908

26

6

Abnormal / Hemizygous

2

Val0022175

8

30

Abnormal/ Homozygous

3

Val0026865

24

10

Abnormal / Hemizygous

4

Val0018480

8

6

Normal / Diploid

5

Val0018585

0

0

Normal / Diploid

6

Val0018540

6

12

Normal / Diploid

Hemizygous
deletion
(% of cells)

Homozygous
deletion
(% of cells)

FISH INTERPRETATION

TABLE 4. Day 2, Run 2, Technologist 2

CASE #

1

Val0020908

30

4

Abnormal / Hemizygous

2

Val0022175

14

34

Abnormal/
Homozygous

3

Val0026865

22

6

Abnormal / Hemizygous

4

Val0018480

14

6

Normal / Diploid

5

Val0018585

4

0

Normal / Diploid

6

Val0018540

2

6

Normal / Diploid
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TABLE 5. Day 3, Run 3, Technologist 1
CASE #

Hemizygous
deletion
(% of cells)

Homozygous
deletion
(% of cells)

FISH INTERPRETATION

1

Val0020908

30

6

Abnormal / Hemizygous

2

Val0022175

2

38

Abnormal/
Homozygous

3

Val0026865

28

2

Abnormal / Hemizygous

4

Val0018480

14

2

Normal / Diploid

5

Val0018585

2

2

Normal / Diploid

6

Val0018540

6

12

Normal / Diploid

Hemizygous
deletion
(% of cells)

Homozygous
deletion
(% of cells)

FISH INTERPRETATION

TABLE 6. Day 3, Run 3, Technologist 2

CASE #

1

Val0020908

32

6

Abnormal / Hemizygous

2

Val0022175

10

30

Abnormal/
Homozygous

3

Val0026865

24

0

Abnormal / Hemizygous

4

Val0018480

12

4

Normal / Diploid

5

Val0018585

0

0

Normal / Diploid

6

Val0018540

10

6

Normal / Diploid
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CLINICAL ACCURACY:
(Gleason 6-7)
Diagnostic Sensitivity =

[20]
[20]+ [4] = 16.67%
Table 7.
VAL-0001132
VAL-0001142
VAL-0001152
VAL-0001158
VAL-0001204
VAL-0002962
VAL-0003074
VAL-0004217
VAL-0005732
VAL-0006333
VAL-0006616
VAL-0026059
VAL-0010531
VAL-0026876
VAL-0027757
VAL-0027669
VAL-0027758
VAL-0028436
VAL-0025618
VAL-0025477

Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Negative/Diploid
Negative/Diploid
Negative/Diploid
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CLINICAL ACCURACY:
(Gleason 8-9)
Diagnostic Sensitivity =

[20]
[20]+ [8] = 71.42%
Table 8.

VAL-0029477
VAL-0003074
VAL-0006567
VAL-0018499
VAL-0019274
VAL-0019573
VAL-0026462
VAL-0026865
VAL-0026910
VAL-0028404
VAL-0028491
VAL-0028845
VAL-0008210
VAL-0026340
VAL-0027758
VAL-0027943
VAL-0028970
VAL-0029662
VAL-0007794
VAL-0028425

Hemizygous Positive
Negative/Diploid
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Homozygous Positive
Homozygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Homozygous Positive
Negative/Diploid
Hemizygous Positive
Homozygous Positive
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CLINICAL ACCURACY:
(Benign Subset)
Diagnostic Specificity =
[20]
[20]+ [0] = 100.0%
Table 9.
VAL-0000080
VAL-0015564
VAL-0015574
VAL-0015577
VAL-0015578
VAL-0015588
VAL-0015595
VAL-0015615
VAL-0015617
VAL-0015662
VAL-0015636
VAL-0015656
VAL-0015658
VAL-0015663
VAL-0015682
VAL-0015685
VAL-0015687
VAL-0015825
VAL-0015568
VAL-0022914

Hemizygous Positive
Negative/Diploid
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Homozygous Positive
Homozygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Negative/Diploid
Hemizygous Positive
Homozygous Positive
Negative/Diploid
Hemizygous Positive
Homozygous Positive
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CHAPTER VIII.

DISCUSSION

If we take the premise that FAS plays a role in at least one of the pathways to
tumorigenesis, what might that look like? Whether it is the byproduct of some inherited genetic
pattern that predisposes certain cells to transition into the progenitors of FAS deletions, PTEN
deletions or the combination, or some environmental or epigenetic threshold, we ultimately end
up with these mutated cells. One could image a stepwise progression where first a FAS gene is
mutated absent of a concomitant PTEN deletion. This FAS deleted cell would be able to, by way
of processes referenced above, escape apoptotic self-destruction and thrive, divide with ever more
degrees of genetic instability until it reaches a critical mass whereby the proximal gene PTEN is
lost as well. At this point not only has the cell attained the ability to escape cytotoxic T cell
destruction, it has lost a major built in tumor suppressor stop gap system in the PTEN pathogenies
model. These cells now no longer have the cell cycle control mechanisms and proliferate
aggressively, all the while going undetected by our cell mediated immunity. Conversely a larger
deletion encompassing FAS and PTEN would presumably follow a similar evolution with the
likelihood of a more rapid progression to the type of aggressive clonal populations seen in
invasive PCA or reach a stage sandwiched between isolated inter-epithelial neoplasia and outright
malignancy. This hypothetical transition point would be characterized by the rapid division of
PTENˉ/FASˉ cells which give way to significant genetic instability and thus harbor the classic
signs of out-of-control chromosomal aneuploidy and/or polysomy.
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Although my sample size is limited and obviously affects the overall certainty of the
study, there seems to be some evidence that this is a feasible explanation in that there is a
simultaneous presence of clearly malignant prostate tumor cells having either heterozygous or
hemizygous deletions of FAS and PTEN genes and the presence of massive prostate tumor cells
with marked increases in chromosomes (polysomic genomes) and amplified genes (see fig.).
Perhaps the best evidence for the progression of PTENˉ/FASˉ or 10q23.2–10q23.3 is seen in
figure 7, whereby both a population of single hemizygous PTENˉ/FASˉ and the marked nuclear
diameter sized nuclei with severe genetic instability or tumorgenecity having increases in
genomes/genes across the whole genome.
In a recent study21 using SNP (Single Nucleotide Polymorphism) “Nex-Gen” sequencing,
Ibeawuchi and colleagues elaborate on a direct connection between simultaneous deletion of both
the PTEN and FAS gene and their role in aggressive Pca clonal subtypes. Their study included a
long clinical follow-up period that ranged from 2.0–9.7 (mean 5.4) years. The sample size and the
longitudinal nature of this research elicits confidence in my original belief that the two deletions
are more than genomic coincidences. I believe it is worth noting that this published paper was
released subsequently to my thesis statement and data collection. Moreover, limitations of
quantitative experiments, in my opinion, are exposed here. In that, the end product of aggressive
tumors relating to concomitant deletion of these two genes are clear in both my investigation and
this published study, however the simi-quanitative nature of FISH microscopy allows for the
morphological and the associated genomic marker changes which inform a more clear evolution
of simple single deletion to the devastating simultaneous deletion of both genes—creating the
dynamic tumor suppressor (PTEN) with inflammatory evading biochemistry (FAS).
This study strengthens my belief in the utility of real-time nucleic acid or polypeptide
fluorescence reporter microscopy (e.g., confocal microscopy) or alternatively the step-wise
“snap-shot” morphological/genomic changes seen in paraffin embedded FISH analysis. Knowing
what happens visually allows for more efficient recognition of neoplastic anomalies such as the
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one I anecdotally discovered and described in this project. PTEN, like other well researched
tumor suppressor and oncogenes, plays a role in multiple neoplastic pathways in multiple tumor
sites with presumably multiple cancer progression rates and clonal subtypes. The question, if
validated, is there a recurrent or reproducible progression that can be detected to aid in treating
this pathogenesis or even manipulated in order to prevent this disease out-right.

TABLE 7
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CHAPTER IX.

CONCLUSION

This project was born from the observation that the four probe flanking construct that in
theory would identify truncation (cutting off) artifact of portions of the chromosome of interest
was not working as intended. That is, instead of there being red (Chromosome 10), green
(WALPAL) and aqua (FAS) present with the gold or orange (PTEN) deleted in indicative cases,
we consistently observed the red chromosomal copy control signal alone by itself. From this
arose many questions. A key question from a clinical accuracy point-of-view was were these the
result of wide spread massive truncation artifact (i.e. the cutting of the entire complement of
PTEN, FAS and WALPAL) or something actually occurring in-situ. I think it is abundantly clear
through the data sets that we have collected, that the pattern of clonal populations that have both
morphological changes associated with prostatic adenocarcinoma and concurrent single copy
control signals with the loss of all signals are not a coincidence. If you compare benign subsets to
the aggressive metastatic subsets, you evolve from sporadic rare events of cells demonstrating
this single copy control red signal to this condition being the norm and actually demarcating a
given clonal population. I decided to make this my research after hearing that FAS was a key
immunological gene. The connection between inflammation and cancer is becoming more
apparent and my anecdotal work observations seem to fit into this newly found etiological player
in neogenesis. The potential connection between these patterns genomically, morphologically or
the type of cancer progression and the immune escape is exciting because further research and
conformation of these connecting processes could offer deeper understanding of cancer’s ability
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to evolve and kill, and ultimately allow us to design better methods of diagnostics, prognostics
and eventual treatment if not cures.
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NEAGATIVE SUBSET ENUMERATION DATA

GP14-1807F

GP14-1732D

GP14-1061G

GP14-1732E

GP14-1485F

GP14-1807E

GP14-1485C

GP14-1997G

GP14-1590C

GP14-2018I
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NEAGATIVE SUBSET ENUMERATION IMAGES

GP14-1807F

GP14-1732D

GP14-1061G

GP14-1732E

GP14-1485F

GP14-1807E

GP14-1485C

GP14-1997G

GP14-1590C

GP14-2018I
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